Skip to main content

Articles By Michael Putman, MD, MSCI

Putman RheumThoughts

Screening and Overdiagnosis of ILD in RA

28 September 2023

Dr. Michael Putman (Milwaukee, WI) reviews his approach to screening for ILD and RA, the potential for overdiagnosis and how this impacts treatment choices. Does this differ from your approach?

Read Article
Risk Option Decision

Hard Conversations: DMARDs and Malignancy

19 September 2023

Cancer is the most difficult DMARD risk to discuss with patients. Few warnings could scare people away from a drug faster than the words “may increase risk of cancer,” yet the risks (even when substantiated) have all been low and may be counterbalanced by the benefits of disease control.

Read Article
question-mark-1872634_640.jpg

Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines

27 December 2022

In the wake of the 2016 AAOS Guidelines, rheumatologists dutifully reduced the dose HCQ take by patients with SLE to some number south of 5mg/kg per day. Though I believe the ophthalmologists correctly interpreted a 2014 paper in JAMA Ophthalmology that quoted a much-higher rate of HCQ associated retinopathy than had previously been appreciated, they and subsequent guidelines published in the field of rheumatology lacked a critical piece of information: what actually happens when you do this?

Read Article
question-mark-1872634_640.jpg

Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines

22 November 2022

In the wake of the 2016 AAOS Guidelines, rheumatologists dutifully reduced the dose HCQ take by patients with SLE to some number south of 5mg/kg per day. Though I believe the ophthalmologists correctly interpreted a 2014 paper in JAMA Ophthalmology that quoted a much-higher rate of HCQ associated retinopathy than had previously been appreciated, they and subsequent guidelines published in the field of rheumatology lacked a critical piece of information: what actually happens when you do this?

Read Article
PMR spotlight

ACR22: Polymyalgia Rheumatica in the Spotlight

14 November 2022

One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting! 

Read Article
lupus_0.jpg

Exciting Data for SLE: Plenaries from #ACR22

12 November 2022

ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!

Read Article
question-mark-2492009_640.jpg

Rheum For Interpretation: Three Tips To Apply RCTs To Your Clinical Practice

28 November 2019

At the 2019 meeting, almost 500 presentations discussed new randomized controlled trials. We are lucky to have so much research activity in our field, but applying an RCT to your daily practice can be challenging. Here are three tips to supercharge your critical appraisal!

Read Article

When Classification And Diagnosis Diverge

21 November 2019

Few rheumatologic diseases have diagnostic criteria, so clinicians often rely on classification criteria to diagnose patients in clinic. Because classification criteria were not designed to be used for these purposes, they have important limitations.

Read Article
×